{"id":43276,"date":"2020-06-26T08:33:33","date_gmt":"2020-06-26T12:33:33","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=43276"},"modified":"2020-06-26T01:35:17","modified_gmt":"2020-06-26T05:35:17","slug":"abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276","title":{"rendered":"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101"},"content":{"rendered":"<p><strong>Abbvie Inc (NYSE:ABBV)<\/strong> and <strong>Alpine Immune Sciences Inc. (NASDAQ:ALPN)<\/strong> have announced an <a href=\"https:\/\/finance.yahoo.com\/news\/alpine-immune-sciences-abbvie-announce-120000148.html\" target=\"_blank\" rel=\"noopener noreferrer\">exclusive global license and option agreement<\/a> for Alpine\u2019s best in class dual ICOS\/CD28 costimulation antagonist, ALPN-101.<\/p>\n<p><strong>AbbVie to co-develop ALPN-101 with Alpine <\/strong><\/p>\n<p>ICOS and CD28 are <a href=\"https:\/\/www.businesswire.com\/news\/home\/20200618005246\/en\/Alpine-Immune-Sciences-AbbVie-Announce-Option-License\" target=\"_blank\" rel=\"noopener noreferrer\">important costimulatory molecules<\/a> playing critical roles in inflammatory autoimmune diseases. Alpine\u2019s ALPN-101 is a potent ICOS and CD28 pathway inhibitor that has shown significant efficacy in several preclinical disease simulations. It demonstrated favorable tolerability and safety, as well as pharmacodynamics and pharmacokinetics; in first human studies in healthy counters.<\/p>\n<p>Tom Hudson, the chief scientific officer of AbbVie, indicated that the company&#8217;s immunology expertise has resulted in incredible breakthroughs in autoimmune disease treatment. Hudson indicated that the double mechanism of action of ALPN-101 has the massive potential of being the next-generation systemic lupus erythematosus and other multiple autoimmune diseases treatment.<\/p>\n<p>As per the terms of the agreement, Alpine is expected to receive a $60 million upfront payment and will receive up to $805 million. This is for exercising the options and depending on future development, regulatory, and commercial milestones. After exercising the option, AbbVie will be the cone to carry clinical development, production as well as commercialization of ALPN-101.<\/p>\n<p><strong>AbbVie\u2019s upadacitinib monotherapy demonstrate skin clearance improvement <\/strong><\/p>\n<p>The company also recently <a href=\"https:\/\/finance.yahoo.com\/news\/rinvoq-upadacitinib-monotherapy-shows-improvement-124500154.html\" target=\"_blank\" rel=\"noopener noreferrer\">announced that its upadacitinib monotherapy<\/a> (15mg and 30mg per day) met primary endpoints or around 75% improvement in the Eczema Area Severity Index.\u00a0 It also includes the Investigator\u2019s Global Assessment for Atopic Dermatitis of almost clear or clear after 16 weeks in adolescents and adults with moderate to chronic atopic dermatitis. This is for systemic therapy candidates with the pivotal third phase study being the first study evaluating RINVOQ\u2019s safety and efficacy in moderate to severe atopic dermatitis treatment.<\/p>\n<p>Those patients in the study that received either 15mg or 30mg upadacitinib monotherapy demonstrated considerable skin clearance improvements. Out of the total patients, 70%\/80%\u00a0 attained EASI 75 after 16 weeks compared to 16% on the control group. Equally, those that received upadacitinib 15mg\/30mg also achieved 48%\/62% vIGA-AD 0\/1 compared to 8% in the control group.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbvie Inc (NYSE:ABBV) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) have announced an exclusive global license and option agreement for Alpine\u2019s best in class dual ICOS\/CD28 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":42568,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3643,1593,14433,14432,14434,1592],"stock_ticker":[14234],"class_list":["post-43276","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-abbvie-inc","tag-abbvie-inc-nyseabbv","tag-alpine-immune-sciences-inc","tag-alpine-immune-sciences-inc-nasdaqalpn","tag-nasdaqalpn","tag-nyseabbv","stock_ticker-abbv","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101 - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101 - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Abbvie Inc (NYSE:ABBV) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) have announced an exclusive global license and option agreement for Alpine\u2019s best in class dual ICOS\/CD28 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-26T12:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101\",\"datePublished\":\"2020-06-26T12:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276\"},\"wordCount\":355,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg\",\"keywords\":[\"AbbVie Inc\",\"AbbVie Inc. (NYSE:ABBV)\",\"Alpine Immune Sciences Inc.\",\"Alpine Immune Sciences Inc. (NASDAQ:ALPN)\",\"NASDAQ:ALPN\",\"NYSE:ABBV\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276\",\"name\":\"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101 - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg\",\"datePublished\":\"2020-06-26T12:33:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg\",\"width\":1000,\"height\":667},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101 - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276","og_locale":"en_US","og_type":"article","og_title":"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101 - Wall Street PR","og_description":"Abbvie Inc (NYSE:ABBV) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) have announced an exclusive global license and option agreement for Alpine\u2019s best in class dual ICOS\/CD28 [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2020-06-26T12:33:33+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101","datePublished":"2020-06-26T12:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276"},"wordCount":355,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg","keywords":["AbbVie Inc","AbbVie Inc. (NYSE:ABBV)","Alpine Immune Sciences Inc.","Alpine Immune Sciences Inc. (NASDAQ:ALPN)","NASDAQ:ALPN","NYSE:ABBV"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276","url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276","name":"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101 - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg","datePublished":"2020-06-26T12:33:33+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/11\/AVEO-Pharmaceuticals.jpg","width":1000,"height":667},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-and-alpine-immune-sciences-inc-nasdaqalpn-enter-partnership-to-develop-alpn-101-43276#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/43276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=43276"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/43276\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/42568"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=43276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=43276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=43276"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=43276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}